Ingrid Thörn

948 total citations
21 papers, 512 citations indexed

About

Ingrid Thörn is a scholar working on Genetics, Pathology and Forensic Medicine and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Ingrid Thörn has authored 21 papers receiving a total of 512 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Ingrid Thörn's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Ingrid Thörn is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). Ingrid Thörn collaborates with scholars based in Sweden, Denmark and United States. Ingrid Thörn's co-authors include Christer Sundström, Gunilla Enblad, Richard Rosenquist, Ola Söderberg, Johan Botling, Magnus Hultdin, Anna Johnson, Ulf Thunberg, Gerard Tobin and Jan Sällström and has published in prestigious journals such as Blood, Scientific Reports and Epilepsia.

In The Last Decade

Ingrid Thörn

19 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ingrid Thörn Sweden 10 276 218 196 106 101 21 512
Francisco José Ortuño Spain 13 173 0.6× 100 0.5× 136 0.7× 17 0.2× 18 0.2× 47 570
Marta Rozans United States 8 87 0.3× 57 0.3× 84 0.4× 39 0.4× 10 0.1× 13 465
Maartje Boon Netherlands 9 43 0.2× 192 0.9× 51 0.3× 43 0.4× 133 1.3× 22 546
Fanny O’Brien United States 15 32 0.1× 100 0.5× 56 0.3× 73 0.7× 14 0.1× 24 818
Mieke Aldenhoven Netherlands 9 104 0.4× 54 0.2× 26 0.1× 37 0.3× 16 0.2× 17 534
Line Buhl Denmark 9 70 0.3× 66 0.3× 32 0.2× 11 0.1× 24 0.2× 20 301
Susan Staba United States 5 169 0.6× 30 0.1× 47 0.2× 82 0.8× 7 0.1× 11 502
Takamitsu Matsushima Japan 11 49 0.2× 36 0.2× 184 0.9× 15 0.1× 18 0.2× 36 416
Nicola C. Venn Australia 15 66 0.2× 68 0.3× 29 0.1× 191 1.8× 50 0.5× 32 658
Maaike de Bie Netherlands 9 54 0.2× 103 0.5× 36 0.2× 36 0.3× 9 0.1× 17 321

Countries citing papers authored by Ingrid Thörn

Since Specialization
Citations

This map shows the geographic impact of Ingrid Thörn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingrid Thörn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingrid Thörn more than expected).

Fields of papers citing papers by Ingrid Thörn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingrid Thörn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingrid Thörn. The network helps show where Ingrid Thörn may publish in the future.

Co-authorship network of co-authors of Ingrid Thörn

This figure shows the co-authorship network connecting the top 25 collaborators of Ingrid Thörn. A scholar is included among the top collaborators of Ingrid Thörn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingrid Thörn. Ingrid Thörn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thörn, Ingrid, Millaray Marincevic, Claes Ladenvall, et al.. (2025). Single-cell sequencing reveals shared clonal signatures in nonmalignant B and tumor cells in T-prolymphocytic leukemia. PubMed. 2(2). 100076–100076.
2.
Amini, Rose‐Marie, Gunilla Enblad, Peter Hollander, et al.. (2019). Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients. BMC Cancer. 19(1). 316–316. 19 indexed citations
3.
Löf, Liza, Linda Arngården, Ulla Olsson‐Strömberg, et al.. (2017). Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia. Scientific Reports. 7(1). 12 indexed citations
4.
Rosenquist, Richard, Ulf Thunberg, Anna Johnson, et al.. (2013). prognosis in chronic lymphocytic leukemia CD38 expression is a poor predictor for VH gene mutational status and. 1 indexed citations
5.
Christiansson, Lisa, Ingrid Thörn, Sara M. Mangsbo, et al.. (2011). Both CD4+ FoxP3+ and CD4+ FoxP3− T cells from patients with B‐cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro. Immunology. 133(3). 296–306. 41 indexed citations
6.
Lönnerholm, Gudmar, Ingrid Thörn, Christer Sundström, et al.. (2010). In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia. Leukemia Research. 35(4). 472–478. 4 indexed citations
7.
Thörn, Ingrid, Erik Forestier, Britt Thuresson, et al.. (2009). Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population‐based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002–2006. European Journal Of Haematology. 84(2). 117–127. 7 indexed citations
8.
9.
Thörn, Ingrid. (2009). Minimal Residual Disease Assessment in Childhood Acute Lymphoblastic Leukemia. KTH Publication Database DiVA (KTH Royal Institute of Technology). 1 indexed citations
10.
Lönnerholm, Gudmar, Ingrid Thörn, Christer Sundström, et al.. (2008). In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. Leukemia Research. 33(1). 46–53. 8 indexed citations
11.
Boström, Hans, Karl‐Johan Leuchowius, Heléne Hallböök, et al.. (2008). U‐2973, a novel B‐cell line established from a patient with a mature B‐cell leukemia displaying concurrent t(14;18) and MYC translocation to a non‐IG gene partner. European Journal Of Haematology. 81(3). 218–225. 5 indexed citations
12.
Thörn, Ingrid, et al.. (2005). Impact of RNA Stabilization on Minimal Residual Disease Assessment in Chronic Myeloid Leukemia.. Blood. 106(11). 4490–4490. 11 indexed citations
13.
Thörn, Ingrid, et al.. (2005). The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.. PubMed. 90(11). 1471–6. 24 indexed citations
14.
Tobin, Gerard, Ulf Thunberg, Anna Johnson, et al.. (2002). Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood. 99(6). 2262–2264. 234 indexed citations
15.
Schmiegelow, Kjeld, Anders H. Johnsen, Finn Ebbesen, et al.. (1990). Gamma‐Aminobutyric Acid Concentration in Lumbar Cerebrospinal Fluid from Patients with Febrile Convulsions and Controls. Acta Paediatrica. 79(11). 1092–1098. 10 indexed citations
16.
Thörn, Ingrid. (1989). The Significance of Electroencephalography in Febrile Convulsions. Cleveland Clinic Journal of Medicine. 56. 4 indexed citations
17.
Thörn, Ingrid. (1975). A CONTROLLED STUDY OF PROFYLACTIC LONG-TERM TREATMENT OF FEBRILE CONVULSIONS WITH PHENOBARBITAL. Acta Neurologica Scandinavica. 51. 67–73. 35 indexed citations
18.
Thörn, Ingrid. (1969). Cerebral symptoms in the newborn. Diagnostic and prognostic significance of symptoms of presumed cerebral origin.. PubMed. Suppl 195:1+–Suppl 195:1+. 7 indexed citations
19.
Thörn, Ingrid. (1962). Primidone and Chlordiazepoxide in Cerebral Palsy. Developmental Medicine & Child Neurology. 4(3). 325–327. 1 indexed citations
20.
Thörn, Ingrid, et al.. (1961). [On the drug treatment of cerebral paralysis in children].. PubMed. 197. 62–5.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francisco José Ortuño Breakdown of academic impact, for papers by Marta Rozans Breakdown of academic impact, for papers by Maartje Boon Breakdown of academic impact, for papers by Fanny O’Brien Breakdown of academic impact, for papers by Mieke Aldenhoven Breakdown of academic impact, for papers by Line Buhl Breakdown of academic impact, for papers by Susan Staba Breakdown of academic impact, for papers by Takamitsu Matsushima Breakdown of academic impact, for papers by Nicola C. Venn Breakdown of academic impact, for papers by Maaike de Bie
Rankless by CCL
2026